Trials / Withdrawn
WithdrawnNCT03801499
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma: a Single-arm, Phase 2 Trial
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib for patients with unresectable intrahepatic cholangiocarcinoma
Detailed description
Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma.No study has evaluated the efficacy and safety of lenvatinib in unresectable intrahepatic cholangiocarcinoma. Thus, the investigators carried out this prospective study to find out it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | 12 mg (or 8 mg) once daily (QD) oral dosing. |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2019-01-11
- Last updated
- 2020-05-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03801499. Inclusion in this directory is not an endorsement.